Tillman Gerngross (Photo by Craig F. Walker/The Boston Globe via Getty Images)
May 10, 2022 07:11 AM EDT
People

Till­man Gern­gross pass­es the Adimab ba­ton af­ter 15 years, mov­ing from CEO to ex­ec­u­tive chair­man role

Amber Tong

A new era is un­fold­ing at Adimab.

Fif­teen years af­ter he co-found­ed the an­ti­body dis­cov­ery shop, Till­man Gern­gross is step­ping down as CEO — hand­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times